Sign In
Buy GTHX
$7.15
+0 (+0%)
At Close: Dec 16, 2024
G1 Therapeutics, Inc. (GTHX) CEO Mark Velleca on Q1 2020 Results - Earnings Call Transcript
02:39pm, Sunday, 10'th May 2020
G1 Therapeutics, Inc. (NASDAQ:GTHX) Q1 2020 Earnings Conference Call May 06, 2020, 16:30 ET Company Participants Jeff Macdonald - Senior Director, IR & Corp
G1 Therapeutics, Inc. (GTHX) Q1 2020 Earnings Call Transcript
02:30pm, Thursday, 07'th May 2020
On today's call, Mark Velleca, Chief Executive Officer; Raj Malik, Chief Medical Officer and Senior Vice President of R&D; and Jen Moses, Chief Financial Officer will provide an overview of the quarte
G1 Therapeutics Provides First Quarter 2020 Corporate and Financial Update
08:01pm, Wednesday, 06'th May 2020
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today provided a corporate and financial update for the first quarter ended March 31, 2020. “We have activated business cont
We Think G1 Therapeutics (NASDAQ:GTHX) Can Afford To Drive Business Growth
11:36am, Wednesday, 06'th May 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle
12:00am, Wednesday, 06'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peak
(Biotech Stocks Hitting 52-week Highs May 5)
• Adverum Biotechnologies...
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
12:00am, Sunday, 03'rd May 2020
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
G1 Therapeutics (NASDAQ:GTHX) Stock Rating Upgraded by Zacks Investment Research
05:32am, Saturday, 02'nd May 2020
G1 Therapeutics (NASDAQ:GTHX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Saturday, Zacks.com reports. The firm presently has a $15.0
G1 Therapeutics to Provide First Quarter 2020 Corporate and Financial Update on May 6, 2020
11:00am, Wednesday, 29'th Apr 2020
RESEARCH TRIANGLE PARK, N.C., April 29, 2020 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and.
Nuveen Asset Management LLC Reduces Stock Position in G1 Therapeutics Inc (NASDAQ:GTHX)
10:38am, Sunday, 26'th Apr 2020
Nuveen Asset Management LLC lowered its stake in G1 Therapeutics Inc (NASDAQ:GTHX) by 1.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission.
G1 Therapeutics (NASDAQ:GTHX) Rating Lowered to Hold at Zacks Investment Research
06:40am, Friday, 24'th Apr 2020
G1 Therapeutics (NASDAQ:GTHX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday, Zacks.com reports. According to Zac
G1 Therapeutics (NASDAQ:GTHX) Upgraded at Zacks Investment Research
05:50am, Thursday, 23'rd Apr 2020
G1 Therapeutics (NASDAQ:GTHX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Thursday, Zacks.com reports. The brokerage presently has
Geode Capital Management LLC Increases Stock Holdings in G1 Therapeutics Inc (NASDAQ:GTHX)
12:16pm, Tuesday, 21'st Apr 2020
Geode Capital Management LLC lifted its stake in shares of G1 Therapeutics Inc (NASDAQ:GTHX) by 3.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities
Exane Derivatives Purchases Shares of 5,738 G1 Therapeutics Inc (NASDAQ:GTHX)
10:20am, Tuesday, 21'st Apr 2020
Exane Derivatives bought a new position in shares of G1 Therapeutics Inc (NASDAQ:GTHX) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institut
Alliancebernstein L.P. Has $1.19 Million Stock Position in G1 Therapeutics Inc (NASDAQ:GTHX)
11:12am, Saturday, 18'th Apr 2020
Alliancebernstein L.P. decreased its holdings in shares of G1 Therapeutics Inc (NASDAQ:GTHX) by 5.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities
Bank of New York Mellon Corp Boosts Holdings in G1 Therapeutics Inc (NASDAQ:GTHX)
09:14am, Saturday, 18'th Apr 2020
Bank of New York Mellon Corp boosted its holdings in shares of G1 Therapeutics Inc (NASDAQ:GTHX) by 1.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchan
